bioAffinity Technologies
BIAF
5 hedge funds and large institutions have $192K invested in bioAffinity Technologies in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.05% more ownership
Funds ownership: 0% → 0.05% (+0.05%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Creative Planning
Overland Park,
Kansas
|
+$124K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$86.5K |
| 3 |
Jane Street
New York
|
+$46.3K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$20.7K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$126 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Creative Planning
Overland Park,
Kansas
| $86K | +$124K | +985 | New |
|
|
2
Citadel Advisors
Miami,
Florida
| $60K | +$86.5K | +686 | New |
|
|
3
Jane Street
New York
| $32K | +$46.3K | +367 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $14K | +$20.7K | +164 | New |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| – | +$126 | +1 | New |
|
BIAF Hedge Fund Activity: Q3 2022 in Review
5 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in bioAffinity Technologies (BIAF) for Q3 2022, worth a combined $192K.
Buyers outnumbered sellers: 5 funds opened new BIAF positions and 0 closed out — a net gain of 5 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Creative Planning, opening a new position worth an estimated $124K.
- 5 institutional investors held bioAffinity Technologies (BIAF) as of Q3 2022, up from 0 in Q2 2022.
- Funds reported $192K of bioAffinity Technologies stock for Q3 2022.
- 5 funds opened new bioAffinity Technologies positions in Q3 2022 and 0 closed out, a net change of +5 holders.
- The largest bioAffinity Technologies buyer in Q3 2022 was Creative Planning, an estimated $124K added.
Based on aggregated 13F filings for Q3 2022.